Vanguard Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Vanguard Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$193M	Buy	47,187,759 +7,407,606	+19%	+$36.7M	﹤0.01%	1569
2025 Q3	$194M	Buy	39,780,153 +3,708,975	+10%	+$19.5M	﹤0.01%	1550
2025 Q2	$183M	Buy	36,071,178 +3,783,201	+12%	+$18.6M	﹤0.01%	1549
2025 Q1	$171M	Sell	32,287,977 -1,722,017	-5%	-$12.6M	﹤0.01%	1551
2024 Q4	$230M	Buy	34,009,994 +9,737,196	+40%	+$65.5M	﹤0.01%	1481
2024 Q3	$160M	Buy	24,272,798 +2,716,252	+13%	+$19.5M	﹤0.01%	1655
2024 Q2	$162M	Buy	21,556,546 +5,541,782	+35%	+$48.3M	﹤0.01%	1609
2024 Q1	$160M	Buy	16,014,764 +349,554	+2%	+$3.89M	﹤0.01%	1642
2023 Q4	$154M	Buy	15,665,210 +158,376	+1%	+$1.13M	﹤0.01%	1641
2023 Q3	$119M	Buy	15,506,834 +4,247,002	+38%	+$42.4M	﹤0.01%	1712
2023 Q2	$84.1M	Buy	11,259,832 +326,248	+3%	+$2.28M	﹤0.01%	1943
2023 Q1	$72.9M	Buy	10,933,584 +876,221	+9%	+$6.95M	﹤0.01%	1985
2022 Q4	$77.5M	Buy	10,057,363 +1,676,377	+20%	+$16.4M	﹤0.01%	1947
2022 Q3	$89.2M	Buy	8,380,986 +1,393,519	+20%	+$14.1M	﹤0.01%	1855
2022 Q2	$56.9M	Buy	6,987,467 +376,090	+6%	+$2.52M	﹤0.01%	2138
2022 Q1	$47.3M	Buy	6,611,377 +497,504	+8%	+$5.29M	﹤0.01%	2333
2021 Q4	$105M	Buy	6,113,873 +3,401,893	+125%	+$64M	﹤0.01%	1961
2021 Q3	$62.4M	Buy	2,711,980 +28,873	+1%	+$818K	﹤0.01%	2236
2021 Q2	$97.9M	Buy	+2,683,107	New	+$79.4M	﹤0.01%	2011

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Vanguard Group's RXRX Position: Q4 2025 in Review

Vanguard Group increased its Recursion Pharmaceuticals (RXRX) stake by 19% in Q4 2025, buying an estimated $36.7M and bringing the position to 47,187,759 shares worth $193M. The position accounts for ﹤0.01% of the portfolio, ranked #1569.

Vanguard Group first reported a position in RXRX in Q2 2021 and has held it in 19 quarters since. The position peaked at $230M in Q4 2024. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Vanguard Group held 47,187,759 shares of Recursion Pharmaceuticals worth $193M as of Q4 2025.
Vanguard Group bought 7,407,606 Recursion Pharmaceuticals shares in Q4 2025, an estimated $36.7M.
Recursion Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1569 holding.
Vanguard Group first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 19 quarters since.
Vanguard Group's Recursion Pharmaceuticals position peaked at $230M in Q4 2024.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.